Scholarlink

Purpose <p>This report presents the secondary outcomes of the ADAPT trial, focusing on the impact of a digital tool designed to support people affected by breast cancer, on breast cancer-specific health-related quality of life (HRQoL) and psychological distress over the first year from diagnosis.</p> Methods <p>Women with early-stage breast cancer were randomly assigned (1:1) to standard care (control) or standard care plus the breast cancer digital tool (intervention). Data were collected using a demographic questionnaire, the European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire BR45 (EORTC QLQ-BR45) for breast cancer-specific HRQoL, and the Hospital Anxiety and Depression Scale (HADS) for psychological distress at baseline, 6&#xa0;weeks, 3&#xa0;months, 6&#xa0;months, and 1&#xa0;year from diagnosis. Linear mixed effect model regression was used to assess the effect of the digital tool over time while correcting for intra-participant correlation.</p> Results <p>There were no significant differences (<i>p</i> &gt; 0.05) in the EORTC QLQ-BR45 scales and items and HADS scores between participants in the intervention and control groups when adjusted for the primary tumor stage.</p> Conclusion <p>The breast cancer digital tool did not have a significant effect on breast cancer–specific HRQoL and psychological distress over time. The results are consistent with the findings of the primary ADAPT paper, which demonstrated that the digital tool did not have a significant effect on patient activation, HRQoL, and health status<i>.</i> There is a need for personalized support and strategies to enhance digital tool adherence, offering more customized self-management approaches for people affected by breast cancer in the future.</p> Trial registration <p>The study was registered at <a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT03866655) on 7 March 2019 (<a href="https://clinicaltrials.gov/study/NCT03866655">https://clinicaltrials.gov/study/NCT03866655</a>). The full protocol is accessible through the following link: <a href="https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3971-6">https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3971-6</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of a digital tool on breast cancer specific health-related quality of life and psychological distress: secondary results from the ADAPT study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Noelle J. M. C. Vrancken Peeters,
  • Sofia Georgopoulou,
  • Rafal Kulakowski,
  • Emma Hainsworth,
  • Emma Lidington,
  • Sophie E. McGrath,
  • Jillian Noble,
  • Leyla Azarang,
  • Olga Husson,
  • Susanne Cruickshank

摘要

Purpose

This report presents the secondary outcomes of the ADAPT trial, focusing on the impact of a digital tool designed to support people affected by breast cancer, on breast cancer-specific health-related quality of life (HRQoL) and psychological distress over the first year from diagnosis.

Methods

Women with early-stage breast cancer were randomly assigned (1:1) to standard care (control) or standard care plus the breast cancer digital tool (intervention). Data were collected using a demographic questionnaire, the European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire BR45 (EORTC QLQ-BR45) for breast cancer-specific HRQoL, and the Hospital Anxiety and Depression Scale (HADS) for psychological distress at baseline, 6 weeks, 3 months, 6 months, and 1 year from diagnosis. Linear mixed effect model regression was used to assess the effect of the digital tool over time while correcting for intra-participant correlation.

Results

There were no significant differences (p > 0.05) in the EORTC QLQ-BR45 scales and items and HADS scores between participants in the intervention and control groups when adjusted for the primary tumor stage.

Conclusion

The breast cancer digital tool did not have a significant effect on breast cancer–specific HRQoL and psychological distress over time. The results are consistent with the findings of the primary ADAPT paper, which demonstrated that the digital tool did not have a significant effect on patient activation, HRQoL, and health status. There is a need for personalized support and strategies to enhance digital tool adherence, offering more customized self-management approaches for people affected by breast cancer in the future.

Trial registration

The study was registered at https://clinicaltrials.gov (NCT03866655) on 7 March 2019 (https://clinicaltrials.gov/study/NCT03866655). The full protocol is accessible through the following link: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3971-6.